The ongoing patent dispute between tech giant Apple Inc. and medical device specialist Masimo Corp. has taken a new turn. The Patent Trial and Appeal Board (PTAB) has recently determined that most of the claims challenged by Apple in two of Masimo’s blood oxygen monitor patents are invalid. This development is part of a complex patent conflict over the Apple Watch.
According to a report by Law360 , the judicial ruling marks the latest event in the vast disagreement that has existed for some time between the two companies. While the details of this ruling seem likely to intensify the dispute, it is noteworthy to recall that the patents in question have core importance to the functionality of the Apple Watch, particularly the device’s capacity to monitor blood oxygen levels.
The patents have had various featured controversies in past infringement claims. These factors have only added components of complexity to the ongoing dispute. These decisions by the PTAB serve as key signposts in navigating the evolving narrative of this contest, cushioning the back-and-forth of revelations and rulings that continue to shape the conversation.
More information about this topic and other developments in the legal field can be found by staying tuned to the rapidly changing world of technology patents and legal news.